CoChat

IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target

Open access
Bruns VI, Nicolaus, Tressler, Elizabeth H., Vendruscolo, Leandro F., Leggio, Lorenzo, Farokhnia, Mehdi · 2024 · Pharmacological Research
Cited by 89

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Addiction is a chronic relapsing disease with high morbidity and mortality. Treatments for addiction include pharmacological and psychosocial interventions; however, currently available medications are limited in number and efficacy. The glucagon-like-peptide-1 (GLP-1) system is emerging as a potential novel pharmacotherapeutic target for alcohol and other substance use disorders (ASUDs). In this review, we summarize and discuss the wealth of available evidence from testing GLP-1 receptor (GLP-1R) agonist medications in preclinical models and humans with ASUDs, possible mechanisms underlying the impact of GLP-1R agonists on alcohol/substance use, gaps in knowledge, and future directions. Most of the research with GLP-1R agonists has been conducted in relation to alcohol use; psychostimulants, opioids, and nicotine have also been investigated. Preclinical evidence suggests that GLP-1R agonists reduce alcohol/substance use and other related outcomes. The main proposed mechanisms are related to reward processing, stress, and cognitive function, as well as broader mechanisms related to satiety, changes in gastric motility, and glucose homeostasis. More in-depth mechanistic studies are warranted. Clinical studies have been limited and their findings have been less conclusive; however, most support the safety and potential efficacy of GLP-1R agonists in ASUD treatment. Identifying preferred compounds, as well as possible subgroups who are most responsive to GLP-1R agonists are some of the key research questions to translate the promising preclinical data into clinical settings. Several clinical trials are underway to test GLP-1R agonists in people with ASUDs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2024.107312

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 80

  1. Connery, 2020, Substance use disorders in global mental health delivery: epidemiology, treatment gap, and implementation of evidence-based treatments, Harv. Rev. Psychiatry, 28, 316, 10.1097/HRP.0000000000000271 · DOI
  2. Carroll, 2021, The profound heterogeneity of substance use disorders: Implications for treatment development, Curr. Dir. Psychol. Sci., 30, 358, 10.1177/09637214211026984 · DOI
  3. Witkiewitz, 2019, Advances in the science and treatment of alcohol use disorder, Sci. Adv., 5, 10.1126/sciadv.aax4043 · DOI · Paper page
  4. Holst, 2007, The physiology of glucagon-like peptide 1, Physiol. Rev., 87, 1409, 10.1152/physrev.00034.2006 · DOI · Paper page
  5. Cork, 2015, Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain, Mol. Metab., 4, 718, 10.1016/j.molmet.2015.07.008 · DOI · Paper page
  6. Graham, 2013, GLP-1 analog attenuates cocaine reward, Mol. Psychiatry, 18, 961, 10.1038/mp.2012.141 · DOI
  7. Graham, 2020, A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain, J. Comp. Neurol., 528, 2445, 10.1002/cne.24905 · DOI
  8. Diz-Chaves, 2020, Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress, Nutrients, 12, 10.3390/nu12113304 · DOI · Paper page
  9. Monney, 2023, GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes, Diabetes Metab., 49, 10.1016/j.diabet.2023.101470 · DOI · Paper page
  10. Nielsen, 2004, Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes, Regul. Pept., 117, 77, 10.1016/j.regpep.2003.10.028 · DOI · Paper page
  11. Tunstall, 2020, Chapter 26 - Rat Models of Alcohol Use Disorder, 967
  12. Vallöf, 2016, The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents, Addict. Biol., 21, 422, 10.1111/adb.12295 · DOI · Paper page
  13. Vallöf, 2020, Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats, Transl. Psychiatry, 10, 238, 10.1038/s41398-020-00923-1 · DOI · Paper page
  14. Liu, 2024, Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice, Neurochem Res., 49, 1061, 10.1007/s11064-023-04093-6 · DOI
  15. Fink-Jensen, 2024, Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys, Psychopharmacology, 10.1007/s00213-024-06637-2 · DOI
  16. Thomsen, 2019, Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys, Psychopharmacol., 236, 603, 10.1007/s00213-018-5089-z · DOI · Paper page
  17. Marty, 2020, Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats, Front. Neurosci., 14, 10.3389/fnins.2020.599646 · DOI · Paper page
  18. Lan, 2012, Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways, Br. J. Pharm., 165, 2799, 10.1111/j.1476-5381.2011.01754.x · DOI · Paper page
  19. McKendrick, 2020, Drug-induced conditioned place preference and its practical use in substance use disorder research, Front. Behav. Neurosci., 14, 10.3389/fnbeh.2020.582147 · DOI · Paper page
  20. Shirazi, 2013, Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward, PLoS One, 8, 10.1371/journal.pone.0061965 · DOI · Paper page
  21. Díaz-Megido, 2023, Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice, Psychopharmacol., 240, 1287, 10.1007/s00213-023-06367-x · DOI
  22. Sørensen, 2016, Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice, Alcohol Clin. Exp. Res, 40, 2247, 10.1111/acer.13199 · DOI
  23. Vallöf, 2019, Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents, Psychoneuroendocrinology, 103, 284, 10.1016/j.psyneuen.2019.02.006 · DOI · Paper page
  24. Vallöf, 2019, Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents, Neuropharmacology, 149, 124, 10.1016/j.neuropharm.2019.02.020 · DOI · Paper page
  25. Allingbjerg, 2023, Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice, Exp. Clin. Psychopharmacol., 31, 612, 10.1037/pha0000620 · DOI
  26. Abtahi, 2018, Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats, Neuroreport, 29, 1046, 10.1097/WNR.0000000000001071 · DOI · Paper page
  27. Colvin, 2020, Brain site-specific inhibitory effects of the GLP-1 analogue exendin-4 on alcohol intake and operant responding for palatable food, Int. J. Mol. Sci., 21, 10.3390/ijms21249710 · DOI · Paper page
  28. Colvin, 2022, Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats, Behav. Brain Res., 421, 10.1016/j.bbr.2021.113726 · DOI
  29. Dixon, 2020, Glucagon-like peptide-1 receptor signaling in the ventral tegmental area reduces alcohol self-administration in male rats, Alcohol Clin. Exp. Res., 44, 2118, 10.1111/acer.14437 · DOI · Paper page
  30. Lanng, 2019, Gluco-metabolic effects of oral and intravenous alcohol administration in men, Endocr. Connect, 8, 1372, 10.1530/EC-19-0317 · DOI
  31. Svartberg, 1998, The ethanol augmentation of glucose-induced insulin secretion is abolished by calcium antagonism with nifedipine: no evidence for a role of glucagon-like peptide-1 (GLP-1), Pancreas, 16, 66, 10.1097/00006676-199801000-00011 · DOI
  32. Arillotta, 2024, Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach, Brain Sci., 14, 10.3390/brainsci14060617 · DOI · Paper page
  33. Bremmer, 2024, Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders, J. Stud. Alcohol Drugs, 85, 5
  34. Quddos, 2023, Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity, Sci. Rep., 13, 10.1038/s41598-023-48267-2 · DOI · Paper page
  35. Wang, 2024, Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population, Nat. Commun., 15, 4548, 10.1038/s41467-024-48780-6 · DOI · Paper page
  36. Leggio, 2023, GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders, Nat. Med., 29, 2993, 10.1038/s41591-023-02634-8 · DOI · Paper page
  37. Hernandez, 2018, Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats, Neuropsychopharmacology, 43, 2000, 10.1038/s41386-018-0010-3 · DOI · Paper page
  38. Hernandez, 2019, Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats, Addict. Biol., 24, 170, 10.1111/adb.12583 · DOI
  39. Hernandez, 2021, GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA, Mol. Psychiatry, 26, 4394, 10.1038/s41380-020-00957-3 · DOI · Paper page
  40. Harasta, 2015, Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior, Neuropsychopharmacology, 40, 1969, 10.1038/npp.2015.47 · DOI
  41. Sørensen, 2015, The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice, Physiol. Behav., 149, 262, 10.1016/j.physbeh.2015.06.013 · DOI · Paper page
  42. Erreger, 2012, Exendin-4 decreases amphetamine-induced locomotor activity, Physiol. Behav., 106, 574, 10.1016/j.physbeh.2012.03.014 · DOI
  43. Chaves Filho, 2020, The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: relevance for bipolar disorder, Prog. Neuropsychopharmacol. Biol. Psychiatry, 99, 10.1016/j.pnpbp.2020.109872 · DOI
  44. Fortin, 2017, Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core, Physiol. Behav., 176, 17, 10.1016/j.physbeh.2017.03.019 · DOI · Paper page
  45. Zhu, 2021, Glucagon-like peptide-1 agonist exendin-4 facilitates the extinction of cocaine-induced condition place preference, Front. Syst. Neurosci., 15, 10.3389/fnsys.2021.711750 · DOI
  46. Zhu, 2021, Glucagon-like peptide-1 analog exendin-4 ameliorates cocaine-mediated behavior by inhibiting toll-like receptor 4 signaling in mice, Front. Pharm., 12
  47. Zhu, 2021, Effects of glucagon-like peptide-1 receptor agonist exendin-4 on the reinstatement of cocaine-mediated conditioned place preference in mice, Front. Behav. Neurosci., 15
  48. You, 2019, Cocaine and cocaine expectancy increase growth hormone, ghrelin, GLP-1, IGF-1, adiponectin, and corticosterone while decreasing leptin, insulin, GIP, and prolactin, Pharm. Biochem. Behav., 176, 53, 10.1016/j.pbb.2018.11.001 · DOI · Paper page
  49. Merkel, 2024, An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking, bioRxiv
  50. Bouhlal, 2017, Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses, Drug Alcohol Depend., 180, 68, 10.1016/j.drugalcdep.2017.07.033 · DOI · Paper page
  51. Yammine, 2023, Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study, J. Addict. Med., 17, 481, 10.1097/ADM.0000000000001147 · DOI
  52. Douton, 2021, Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats, Behav. Pharm., 32, 265, 10.1097/FBP.0000000000000609 · DOI · Paper page
  53. Douton, 2022, Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats, Behav. Pharm., 33, 364, 10.1097/FBP.0000000000000685 · DOI · Paper page
  54. Evans, 2022, Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats, Brain Res. Bull., 189, 163, 10.1016/j.brainresbull.2022.08.022 · DOI
  55. Zhang, 2021, A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats, Neuropharmacology, 192, 10.1016/j.neuropharm.2021.108599 · DOI
  56. Urbanik, 2022, Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats, Brain Res. Bull., 189, 155, 10.1016/j.brainresbull.2022.08.023 · DOI
  57. Łupina, 2020, The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats, Neurochem Int., 133, 10.1016/j.neuint.2019.104616 · DOI
  58. Listos, 2022, Linagliptin, a selective dipeptidyl peptidase-4 inhibitor, reduces physical and behavioral effects of morphine withdrawal, Molecules, 27, 10.3390/molecules27082478 · DOI · Paper page
  59. Appenzeller, 2024, Obes. Drug cuts opiate craving
  60. Herman, 2023, Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats, Psychopharmacol., 240, 1373, 10.1007/s00213-023-06376-w · DOI
  61. Falk, 2023, GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity, Cell Rep., 42, 10.1016/j.celrep.2023.112466 · DOI
  62. Yammine, 2021, Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial, Nicotine Tob. Res., 23, 1682, 10.1093/ntr/ntab066 · DOI
  63. Lengsfeld, 2023, Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial, EClinicalMedicine, 57, 10.1016/j.eclinm.2023.101865 · DOI · Paper page
  64. Lüthi, 2024, Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial, EClinicalMedicine, 68, 10.1016/j.eclinm.2024.102429 · DOI · Paper page
  65. Farokhnia, 2020, Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study, Transl. Psychiatry, 10, 71, 10.1038/s41398-020-0756-3 · DOI
  66. Wang, 2024, Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study, Mol. Psychiatry, 10.1038/s41380-024-02498-5 · DOI · Paper page
  67. Doggrell, 2018, Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?, Expert Opin. Drug Metab. Toxicol., 14, 371, 10.1080/17425255.2018.1441286 · DOI
  68. Knudsen, 2016, Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus, J. Diabetes Invest., 7 Suppl 1, 56, 10.1111/jdi.12463 · DOI · Paper page
  69. Wise, 2008, Dopamine and reward: the anhedonia hypothesis 30 years on, Neurotox. Res., 14, 169, 10.1007/BF03033808 · DOI · Paper page
  70. Koob, 2023, Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit/stress surfeit disorder, Curr. Top. Behav. Neurosci., 10.1007/7854_2023_424 · DOI
  71. Mansur, 2017, Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study, J. Affect. Disord., 207, 114, 10.1016/j.jad.2016.09.056 · DOI · Paper page
  72. Zhang, 2019, Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies, Diabetes Care, 42, 1274, 10.2337/dc18-2584 · DOI
  73. Watson, 2019, Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease, Behav. Brain Res., 356, 271, 10.1016/j.bbr.2018.08.006 · DOI · Paper page
  74. Kopp, 2024, Type 2 diabetes mellitus/obesity drugs: a neurodegenerative disorders savior or a bridge too far?, Ageing Res. Rev., 98, 10.1016/j.arr.2024.102343 · DOI
  75. Ghidewon, 2022, Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms, Diabetes Obes. Metab., 24, 1010
  76. Kinzig, 2002, The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness, J. Neurosci., 22, 10470, 10.1523/JNEUROSCI.22-23-10470.2002 · DOI · Paper page
  77. Thiele, 1997, Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats, Am. J. Physiol. Regul. Integr. Comp. Physiol., 272, R726, 10.1152/ajpregu.1997.272.2.R726 · DOI · Paper page
  78. Seeley, 2000, The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride, J. Neurosci., 20, 1616, 10.1523/JNEUROSCI.20-04-01616.2000 · DOI · Paper page
  79. Heilig, 2021, Addiction as a brain disease revised: why it still matters, and the need for consilience, Neuropsychopharmacology, 46, 1715, 10.1038/s41386-020-00950-y · doi:10.1038/s41386-020-00950-y
  80. Ørskov, 1996, Glucagon-like peptide i receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I, Diabetes, 45, 832, 10.2337/diab.45.6.832 · DOI · Paper page

Cited by

See all 89

Metadata

Authors
Bruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2024-09
Volume
207
Pages
107312
ISSN
1043-6618 (ISSN-L)
OpenAlex
W4400766615
Cited by
89
References
45
FWCI
23.27
Type
journal article
Language
en
Open access
gold
Licence
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. https://app.cochat.ai/papers/10.1016/j.phrs.2024.107312
The paper
Bruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024). IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107312

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.